LRMR 7.76 Larimar Therapeutics, Inc.
| Range: | 2.18-13.68 | Vol Avg: | 553521 | Last Div: | 0 | Changes: | 0.21 |
| Beta: | 0.76 | Cap: | 0.45B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Jun 19 2014 | Empoloyees: | 42 | ||
| CUSIP: | 517125100 | CIK: | 0001374690 | ISIN: | US5171251003 | Country: | US |
| CEO: | Dr. Carole S. Ben-Maimon M.D. | Website: | https://www.larimartx.com | ||||
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow